GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cipla Ltd (BOM:500087) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Cipla (BOM:500087) Future 3-5Y EPS without NRI Growth Rate : 2.75 (As of Jul. 16, 2025)


View and export this data going back to 1992. Start your Free Trial

What is Cipla Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Cipla's Future 3-5Y EPS without NRI Growth Rate is 2.75.

Competitive Comparison of Cipla's Future 3-5Y EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Cipla's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cipla's Future 3-5Y EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cipla's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Cipla's Future 3-5Y EPS without NRI Growth Rate falls into.


;
;

Cipla  (BOM:500087) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Cipla Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Cipla's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Cipla Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cipla Ltd (BOM:500087) » Definitions » Future 3-5Y EPS without NRI Growth Rate
Comparable Companies
NSE:TORNTPHARM BOM:500124 BOM:532321 BOM:543904 BOM:500257 BOM:500488 NSE:DIVISLAB NSE:AUROPHARMA NSE:ALKEM BOM:532296 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 XTAE:TEVA SHSE:688506
Traded in Other Exchanges
CIPLA:India
Address
Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, IND, 400 013
Website
https://www.cipla.com
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.

Cipla Headlines

No Headlines